Table 1 Correlation of clinical parameters of 31 patients with expression of EMX2 and overall survival
From: EMX2 gene expression predicts liver metastasis and survival in colorectal cancer
Characteristic | n | EXM2high(%) | EXM2low(%) | P-value (Fisher’s exact test) | Mean overall survival (months) | P-value (Log-rank test) |
|---|---|---|---|---|---|---|
Gender | ||||||
 Male | 23 | 11(47,83%) | 12(52,17%) | 0,1552 | 55,2 | 0,7989 |
 Female | 8 | 3(37,50%) | 5(62,50%) |  | 52,1 |  |
Age at operation | ||||||
  < median = 67 | 17 | 7(41,18%) | 10(58,82%) | 0,2559 | 51,4 | 0,5648 |
  < median = 67 | 14 | 7(50,00%) | 7(50,00%) |  | 57,7 |  |
Localisation | ||||||
 Colon | 16 | 6(37,50%) | 10(62,50%) | 0,0649 | 54,9 | 0,9256 |
 Rectum | 15 | 8(53,33%) | 7(46,67%) |  | 53,9 |  |
T stage | ||||||
 T1 | 0 | 0 | 0 | 0,0413 | N.A. | 0,2123 |
 T2 | 4 | 3(75,00%) | 1(25,00%) |  | 78,5 |  |
 T3 | 22 | 11(50,00%) | 11(50,00%) |  | 51,9 |  |
 T4 | 5 | 0(0,00%) | 5(100%) |  | 46,4 |  |
N stage | ||||||
 N1 | 17 | 9(52,94%) | 8(47,06%) | 0,0226 | 54,8 | 0,9444 |
 N2 | 14 | 5(35,71%) | 9(64,29%) |  | 54,0 |  |
Resection margin | ||||||
 R0 | 31 | 14(45,16%) | 17(54,84%) | N.A. | 54,4 | N.A |
 R1 | 0 | 0 | 0 |  | N.A. |  |
 R2 | 0 | 0 | 0 |  | N.A. |  |
 Rx | 0 | 0 | 0 |  | N.A. |  |
Occurrence of liver metastasis | ||||||
 Yes | 14 | 3(21,43%) | 11(78,57%) | 0.0001 | 43,0 | 0,0415 |
 No | 17 | 11(64,71%) | 6(35,29%) |  | 63,8 |  |
Perioperative chemotherapy | ||||||
 Yes | 27 | 12(44,44%) | 15(55,56%) | 0,4788 | 52,6 | 0,3842 |
 No | 4 | 2(50,00%) | 2(50,00%) |  | 66,7 |  |